Terms: = Lung cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Clinical Outcome
15 results:
1. Interstitial lung Abnormalities in Patients With Locally Advanced Esophageal cancer: Prevalence, Risk Factors, and clinical Implications.
Tseng SC; Hino T; Hatabu H; Park H; Sanford NN; Lin G; Nishino M; Mamon H
J Comput Assist Tomogr; 2022 Nov-Dec 01; 46(6):871-877. PubMed ID: 35995596
[TBL] [Abstract] [Full Text] [Related]
2. B cell-related gene signature and cancer immunotherapy response.
Lundberg A; Li B; Li R
Br J Cancer; 2022 Apr; 126(6):899-906. PubMed ID: 34921229
[TBL] [Abstract] [Full Text] [Related]
3. Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With lung cancer.
Yuan Q; Cai T; Hong C; Du M; Johnson BE; Lanuti M; Cai T; Christiani DC
JAMA Netw Open; 2021 Jul; 4(7):e2114723. PubMed ID: 34232304
[TBL] [Abstract] [Full Text] [Related]
4. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.
Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X
J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758
[TBL] [Abstract] [Full Text] [Related]
5. clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell lung cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract] [Full Text] [Related]
6. Suppression of Musashi‑2 by the small compound largazole exerts inhibitory effects on malignant cells.
Wang M; Sun XY; Zhou YC; Zhang KJ; Lu YZ; Liu J; Huang YC; Wang GZ; Jiang S; Zhou GB
Int J Oncol; 2020 May; 56(5):1274-1283. PubMed ID: 32319553
[TBL] [Abstract] [Full Text] [Related]
7. Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases.
Wu B; Ingersoll K; Jug R; Yang LH; Luedke C; Lo A; Su P; Liu X; Rehder C; Gong J; Lu CM; Wang E
Am J Clin Pathol; 2017 Dec; 149(1):55-66. PubMed ID: 29228125
[TBL] [Abstract] [Full Text] [Related]
8. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract] [Full Text] [Related]
9. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
Paz-Ares L; Soulières D; Moecks J; Bara I; Mok T; Klughammer B
J Cell Mol Med; 2014 Aug; 18(8):1519-39. PubMed ID: 25100284
[TBL] [Abstract] [Full Text] [Related]
10. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract] [Full Text] [Related]
11. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
Herman SE; Johnson AJ
Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
[TBL] [Abstract] [Full Text] [Related]
12. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (bcrP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract] [Full Text] [Related]
13. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
Shibata T; Hanada S; Kokubu A; Matsuno Y; Asamura H; Ohta T; Sakamoto M; Hirohashi S
Cancer Sci; 2007 Jul; 98(7):985-91. PubMed ID: 17459062
[TBL] [Abstract] [Full Text] [Related]
14. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract] [Full Text] [Related]
15. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
[TBL] [Abstract] [Full Text] [Related]
